Tammy Forrester

3.5k total citations · 3 hit papers
29 papers, 2.1k citations indexed

About

Tammy Forrester is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pharmacology. According to data from OpenAlex, Tammy Forrester has authored 29 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Pharmacology. Recurrent topics in Tammy Forrester's work include Advanced Breast Cancer Therapies (18 papers), HER2/EGFR in Cancer Research (5 papers) and Breast Cancer Treatment Studies (4 papers). Tammy Forrester is often cited by papers focused on Advanced Breast Cancer Therapies (18 papers), HER2/EGFR in Cancer Research (5 papers) and Breast Cancer Treatment Studies (4 papers). Tammy Forrester collaborates with scholars based in United States, Japan and Spain. Tammy Forrester's co-authors include Masakazu Toi, Angelo Di Leo, Susana Barriga, Matthew P. Goetz, Martin Frenzel, Nawel Bourayou, Jens Huober, Shani Paluch–Shimon, Joohyuk Sohn and In Hae Park and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Tammy Forrester

29 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

2019 407 citations Stephen Johnston, Miguel Martín et al. npj Breast Cancer profile →
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

2023 220 citations Thomas A. Wadden, Ariana M. Chao et al. Nature Medicine profile →

Peers

Countries citing papers authored by Tammy Forrester

Since Specialization

Citations

This map shows the geographic impact of Tammy Forrester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tammy Forrester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tammy Forrester more than expected).

Fields of papers citing papers by Tammy Forrester

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tammy Forrester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tammy Forrester. The network helps show where Tammy Forrester may publish in the future.

Co-authorship network of co-authors of Tammy Forrester

This figure shows the co-authorship network connecting the top 25 collaborators of Tammy Forrester. A scholar is included among the top collaborators of Tammy Forrester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tammy Forrester. Tammy Forrester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	#1702836 Tirzepatide Improved Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-3 phase 3 trial 2024 ·Endocrine Practice ·(unknown), Theresa Hunter, Dachuang Cao, Tammy Forrester, (unknown)	5
2	Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3) 2024 ·Diabetologie und Stoffwechsel ·Thomas A. Wadden, Ariana M. Chao, Sriram Machineni, Robert F. Kushner, Jamy D. Ard, Gitanjali Srivastava, Bruno Halpern, Shuyu Zhang, Jiaxun Chen, Mathijs C. Bunck, (unknown), Tammy Forrester, (unknown)	1
3	8366 Weight Reduction is Associated with Improved Quality of Life in Patients in SURMOUNT-3 2024 ·Journal of the Endocrine Society ·(unknown), Dachuang Cao, Tammy Forrester, Jochen Brumm	1
4	1676-P: Tirzepatide Improved Mental and Psychosocial Function in Adults with Obesity or Overweight in the SURMOUNT-3 Trial 2024 ·Diabetes ·Theresa Hunter, (unknown), Tammy Forrester, (unknown), Ariana M. Chao	3
5	Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial breakdown → 2023 ·Nature Medicine ·Thomas A. Wadden, Ariana M. Chao, Sriram Machineni, Robert F. Kushner, Jamy D. Ard, Gitanjali Srivastava, Bruno Halpern, Shuyu Zhang, Jiaxun Chen, Mathijs C. Bunck, Nadia N. Ahmad, Tammy Forrester	220
6	Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: disease characteristics and endocrine therapy choice by menopausal status 2022 ·Geburtshilfe und Frauenheilkunde ·(unknown), (unknown), Jane Beith, Eriko Tokunaga, Jessica Reyes Contreras, (unknown), Tammy Forrester, (unknown), (unknown), (unknown)	1
7	153P Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: Disease characteristics and endocrine therapy choice by menopausal status 2021 ·Annals of Oncology ·Shani Paluch–Shimon, (unknown), Jane Beith, Eriko Tokunaga, Jessica Reyes Contreras, (unknown), Tammy Forrester, (unknown), (unknown), Nadia Harbeck	1
8	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer breakdown → 2019 ·npj Breast Cancer ·Stephen Johnston, Miguel Martín, Angelo Di Leo, Seock‐Ah Im, Ahmad Awada, Tammy Forrester, Martin Frenzel, Molly Catherine Hardebeck, Joanne Cox, Susana Barriga, Masakazu Toi, Hiroji Iwata, Matthew P. Goetz	407
9	Abstract 4458: Clinical significance ofPIK3CAandESR1mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant 2019 ·Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva‐Maria Grischke, Antonio Llombart‐Cussac, Hatem Soliman, Lacey M. Litchfield, Sameera R. Wijayawardana, Tammy Forrester, Valerie M. Jansen, George W. Sledge	1
10	Abstract P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies 2018 ·Cancer Research ·Angelo Di Leo, (unknown), (unknown), Masakazu Toi, Tammy Forrester, Shivani Nanda, Andrew Koustenis, Nawel Bourayou, SR Johnston	2
11	Abstract GS6-02: The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies 2018 ·Cancer Research ·(unknown), Joyce O’Shaughnessy, (unknown), Miguel Martín, Yi Lin, Tammy Forrester, (unknown), (unknown), Angelo Di Leo, Stephen Johnston	8
12	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer breakdown → 2017 ·Journal of Clinical Oncology ·Matthew P. Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch–Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin‐Cheh Chen, Luís Manso, Orit Freedman, Georgina Garnica Jaliffe, Tammy Forrester, Martin Frenzel, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Angelo Di Leo	1125
13	MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer 2017 ·Annals of Oncology ·Angelo Di Leo, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch–Shimon, Jens Huober, (unknown), Olivier Trédan, (unknown), Luís Manso, Orit Freedman, Georgina Garnica Jaliffe, Tammy Forrester, Martin Frenzel, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Matthew P. Goetz	13
14	Abstract OT2-01-08: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2- metastatic breast cancer 2017 ·Cancer Research ·Véronique Dièras, Erika Hamilton, (unknown), Tammy Forrester, (unknown)	1
15	monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+ advanced breast cancer 2016 ·Annals of Oncology ·Sara M. Tolaney, Nawel Bourayou, Shom Goel, Tammy Forrester, Fabrice André	2
16	The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials 2016 ·Lupus ·Brad H. Rovin, Mary Anne Dooley, Jai Radhakrishnan, Ellen M. Ginzler, Tammy Forrester, Pamela W. Anderson	25
17	Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease 2012 ·International Psychogeriatrics ·Paula T. Trzepacz, Jeffrey L. Cummings, (unknown), Tammy Forrester, (unknown), Ellen B. Dennehy, Brian A. Willis, Catherine L Shuler, Linda B. Tabas, Constantine G. Lyketsos	43
18	Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease 2012 ·Alzheimer s & Dementia ·Paula T. Trzepacz, Peng Yu, (unknown), Brian A. Willis, Tammy Forrester, Linda B. Tabas, Adam J. Schwarz, Andrew J. Saykin, (unknown)	107
19	Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder 2011 ·Diabetes Obesity and Metabolism ·Todd A. Hardy, Robert R. Henry, Tammy Forrester, (unknown), (unknown), David M. Marks, Sunder Mudaliar	14
20	Influence of sub-syndromal symptoms after remission from manic or mixed episodes 2006 ·The British Journal of Psychiatry ·Mauricio Tohen, Charles L. Bowden, Joseph R. Calabrese, Daniel Lin, Tammy Forrester, Roy H. Perlis, Athanasios Koukopoulos, Lakshmi N. Yatham, Heinz Grunze	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact